Protein Acetylation in the Cardiorenal Axis The Promise of Histone Deacetylase Inhibitors

作者：Bush Erik W^*; McKinsey Timothy A

来源：Circulation Research, 2010, 106(2): 272-284.

DOI：10.1161/CIRCRESAHA.109.209338

• acetylation
• histone deacetylase
• heart failure
• kidney failure
• fibrosis

Acetylation of histone and nonhistone proteins provides a key mechanism for controlling signaling and gene expression in heart and kidney. Pharmacological inhibition of protein deacetylation with histone deacetylase ( HDAC) inhibitors has shown promise in preclinical models of cardiovascular and renal disease. Efficacy of HDAC inhibitors appears to be governed by pleiotropic salutary actions on a variety of cell types and pathophysiological processes, including myocyte hypertrophy, fibrosis, inflammation and epithelial-to-mesenchymal transition, and occurs at compound concentrations below the threshold required to elicit toxic side effects. We review the roles of acetylation/deacetylation in the heart and kidney and provide rationale for extending HDAC inhibitors into clinical testing for indications involving these organs. (Circ Res. 2010; 106: 272-284.)

• 出版日期2010-2-5